Загрузка видео...
Не удалось загрузить видео
Today we are announcing a $311M Series E to bring pharma into the 21st century. Enveda started with a thesis: a molecule that evolution has already refined is a better place to begin than one designed from scratch. This year, two first-in-class molecules discovered by Enveda (ENV-294 and ENV-308)... show more
29,657 просмотров • 4 дней назад •via X (Twitter)
Комментарии: 9

Zavain Dar4 дней назад
LFG

Jason Kelly4 дней назад
woohoo!!! congrats @viswacolluru !! 🎉🎉

Pablo Lubroth4 дней назад
🔥🔥

Bilal Zuberi // Red Glass Ventures4 дней назад
Go @viswacolluru! 🚀

Sam Davis4 дней назад
CONGRATS @viswacolluru!

Aaron Blotnick4 дней назад
Huge news Congrats y'all!

Ben Casnocha4 дней назад
Amazing!

Manuel Grossmann4 дней назад
Congrats @viswacolluru!!

Kuldeep Pisda4 дней назад
Two positive human readouts is the real test for the evolution-refined thesis, since natural products often stall on synthesis at scale. Did ENV-294 or ENV-308 need a new synthetic route first?
